Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Patient and service user engagement in research: a systematic review and synthesized framework
Shippee, Nathan D. , Garces, Juan Pablo Domecq , Lopez, Gabriela J. Prutsky, Elraiyah, Tarig, Nabhan, Mohammed , Brito, Juan P. , Boehmer, Kasey B., Hasan, Rim, Firwana, Belal , Erwin, Patricia J., Montori, Víctor M. , Murad, M. Hassan , Domecq Garces, Juan Pablo, Prutsky Lopez, Gabriela J, Elraiyah, Tarig A, Boehmer, Kasey, López, Gabriela, Wang, Zhen , Murad, M Hassan , Montori, Victor M , Brito, Juan P , Domecq Graces, Juan Pablo , Shippee, Nathan

Health Expectations | June 4, 2013 | Volume: 18 | Issue: 5 | Pages: 1151-1166

10.1111/hex.12090 | PMID 23731468 Get It

Abstract Background There is growing attention towards increasing patient and service user engagement ( PSUE ) in biomedical and health services research. Existing variations in language and design inhibit reporting and indexing, which are crucial to comparative effectiveness in determining best practices. Objective This paper utilizes a systematic review and environmental scan to derive an evidence‐based framework for PSUE . Design A metanarrative systematic review and environmental scan/manual search using scientific databases and other search engines, along with feedback from a patient advisory group ( PAG ). Eligible sources English‐language studies, commentaries, grey literature and other sources (including systematic and non‐systematic reviews) pertaining to patient and public involvement in biomedical and health services research. Data extracted Study description (e.g. participant demographics, research setting) and design, if applicable; frameworks, conceptualizations or planning schemes for PSUE ‐related endeavours; and methods for PSUE initiation and gathering patients'/service users' input or contributions. Results Overall, 202 sources were included and met eligibility criteria; 41 of these presented some framework or conceptualization of PSUE . Sources were synthesized into a two‐part framework for PSUE: (i) integral PSUE components include patient and service user initiation, reciprocal relationships, colearning and re‐assessment and feedback, (ii) sources describe PSUE at several research stages, within three larger phases: preparatory, execution and translational. Discussion and Conclusions Efforts at developing a solid evidence base on PSUE are limited by the non‐standard and non‐empirical nature of much of the literature. Our proposed two‐part framework provides a standard structure and language for reporting and indexing to support comparative effectiveness and optimize PSUE .
Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: Findings From the ACCENT Database
McCleary, Nadine J. , Meyerhardt, Jeffrey A. , Green, Erin , Yothers, Greg , Gramont, Aimery de , Twelves, Christopher , Saltz, Leonard B. , Haller, Daniel G. , Sargent, Daniel J. , Cutsem, Eric Van , O’Connell, Michael J. , Sargent, Daniel J , Saltz, Leonard , Meyerhardt, Jeffrey A , Yothers, Greg

Journal of Clinical Oncology | June 4, 2013 | Volume: 31 | Issue: 20 | Pages: 2600-2606

10.1200/jco.2013.49.6638 | PMID 23733765 Get It

Purpose Prior studies have suggested that patients with stage II/III colon cancer receive similar benefit from intravenous (IV) fluoropyrimidine adjuvant therapy regardless of age. Combination regimens and oral fluorouracil (FU) therapy are now standard. We examined the impact of age on colon cancer recurrence and mortality after adjuvant therapy with these newer options. Patients and Methods We analyzed 11,953 patients age < 70 and 2,575 age ≥ 70 years from seven adjuvant therapy trials comparing IV FU with oral fluoropyrimidines (capecitabine, uracil, or tegafur) or combinations of fluoropyrimidines with oxaliplatin or irinotecan in stage II/III colon cancer. End points were disease-free survival (DFS), overall survival (OS), and time to recurrence (TTR). Results In three studies comparing oxaliplatin-based chemotherapy with IV FU, statistically significant interactions were not observed between treatment arm and age (P interaction = .09 for DFS, .05 for OS, and .36 for TTR), although the stratified point estimates suggested limited benefit from the addition of oxaliplatin in elderly patients (DFS hazard ratio [HR], 0.94; 95% CI, 0.78 to 1.13; OS HR, 1.04; 95% CI, 0.85 to 1.27). No significant interactions by age were detected with oral fluoropyrimidine therapy compared with IV FU; noninferiority was supported in both age populations. Conclusion Patients age ≥ 70 years seemed to experience reduced benefit from adding oxaliplatin to fluoropyrimidines in the adjuvant setting, although statistically, there was not a significant effect modification by age, whereas oral fluoropyrimidines retained their efficacy.
ADAM17 Controls Endochondral Ossification by Regulating Terminal Differentiation of Chondrocytes
Hall, K. , Hill, Daniel, Otero, Miguel , Plumb, Darren A., Froemel, Dara, Dragomir, C., Maretzky, Thorsten , Boskey, Adele L. , Selleri, Licia , Blobel, Carl , Crawford, Howard C. , Goldring, Mary B.

Molecular and Cellular Biology | June 4, 2013 | Volume: 33 | Issue: 16 | Pages: 3077-3090

10.1128/mcb.00291-13 | PMID 23732913 Get It

Predictive endoscopy: Form follows function
Wallace, Michael B. , Wallace, Michael B

Endoscopy | June 3, 2013 | Volume: 45 | Issue: 06 | Pages: 419-420

10.1055/s-0033-1344143 | PMID 23733724 Get It

Teaching Neuro Images : Hydroxychloroquine-induced vacuolar myopathy
Ghosh, Partha S. , Swift, D. J., Engel, Andrew G.

Neurology | June 3, 2013 | Volume: 80 | Issue: 23 | Pages: No page available

10.1212/wnl.0b013e318295d6f4 | PMID 23733558 Get It

Creation of the AAN Global Health Section, Part II
Lee, Amy C., Chin, Jerome H. , Birbeck, Gretchen L. , Bower, James H., Meyer, Ana-Claire L.

Neurology | June 3, 2013 | Volume: 80 | Issue: 23 | Pages: 2151-2153

10.1212/wnl.0b013e318295d6bc | PMID 23733551 Get It

Impact of fasting on human brain acid‐base homeostasis using natural abundance 13C and 31P MRS
Sailasuta, Napapon, Harris, Kent, Tran, Thao , Ross, Brian D. , Abulseoud, Osama A.

Journal of Magnetic Resonance Imaging | June 3, 2013 | Volume: 39 | Issue: 2 | Pages: 398-401

10.1002/jmri.24166 | PMID 23733582 Get It

PurposeTo use 13C magnetic resonance spectroscopy (MRS) and 31P MRS to develop a direct assay for regional [HCO3−] in the human brain and to define brain pH and physiological response of [HCO3−] to fasting.Materials and MethodsSeven healthy subjects underwent MRS examinations on a 1.5T MRI scanner. Subjects were well fed with repeated examinations performed after 4 and 12 hours of fasting. Proton noise decoupling 13C MRS were acquired using pulse and acquired acquisition while 31P MRS were acquired using a 2D chemical shift imaging method with relaxation time (TR) of 2 seconds.ResultsFasting brain bicarbonate concentrations (6.7 ± 2.5 mM for 12‐hour fasting, P = 0.002 and 8.3 ± 2.1 mM for 4‐hour fasting, P = 0.015) are significantly reduced compared to fed state (11.6 ± 1.3 mM). However, no significant difference in brain pH was observed, confirming the critical role of pCO2 in intracerebral pH homeostasis.ConclusionWe demonstrated that the intracellular HCO3− in human brain is readily modified by diet but appears to have no measurable effect on cerebral pH. Natural abundance 13C can provide useful information relevant to human brain pH homeostasis by providing information for HCO3−. J. Magn. Reson. Imaging 2014;39:398–401. © 2013 Wiley Periodicals, Inc.
Shedding of Soluble Epidermal Growth Factor Receptor (sEGFR) Is Mediated by a Metalloprotease/Fibronectin/Integrin Axis and Inhibited by Cetuximab
Wilken, Jason A. , Pérez-Torres, Marianela, Nieves-Alicea, René, Cora, Elsa M., Christensen, Trace , Baron, Andre T. , Maihle, Nita J.

Biochemistry | June 3, 2013 | Volume: 52 | Issue: 26 | Pages: 4531-4540

10.1021/bi400437d | PMID 23731208 Get It

Comment on Advances in Urologic Surgery Special Edition
Thiel, David D.

Journal of Laparoendoscopic & Advanced Surgical Techniques | June 3, 2013 | Volume: 23 | Issue: 6 | Pages: 487-488

10.1089/lap.2013.9997 | PMID 23731079 Get It

Left Cardiac Sympathetic Denervation in Long QT Syndrome
Bos, J. Martijn , Bos, Katy M., Johnson, Jonathan N. , Moir, Christopher R. , Ackerman, Michael J. , Bos, Johan M

Circulation: Arrhythmia and Electrophysiology | June 1, 2013 | Volume: 6 | Issue: 4 | Pages: 705-711

10.1161/circep.113.000102 | PMID 23728945 Get It

Background— Long QT syndrome (LQTS) is a potentially lethal but highly treatable cardiac channelopathy. Treatment options include pharmacotherapy, device therapy, and left cardiac sympathetic denervation (LCSD). Here, we sought to determine the characteristics of LQTS patients who have had ≥1 LQTS-related breakthrough cardiac event (BCE) after LCSD. Methods and Results— We performed retrospective chart review for 52 consecutive patients (24 males; mean age at diagnosis, 10.0±10 years; mean QTc, 528±74 ms) with LQTS who underwent LCSD between 2005 and 2010 (mean age at LCSD, 14.1±10 years) and have been followed up for 3.6±1.3 years. A BCE was defined as either (1) an appropriate ventricular fibrillation-terminating implantable cardioverter defibrillator shock or (2) arrhythmogenic syncope, seizures, or aborted cardiac arrest after LCSD. Thirty-three patients (61%) had LCSD as primary prevention because of either high-risk assessment or β-blocker intolerance. So far, 12 of 52 (23%) patients (7 males) have experienced ≥1 BCE post LCSD. The clinical phenotype of patients with BCEs was significantly more severe than patients without a BCE. No BCEs were seen in patients undergoing LCSD for β-blocker intolerance (0/12 versus 17/40; P <0.001). Conclusions— Although a marked reduction in number of cardiac events is usually seen after LCSD, ≈50% of high-risk LQTS patients have experienced ≥1 post-LCSD breakthrough. Therefore, LCSD must not be viewed as curative or as an alternative in implantable cardioverter defibrillator for high-risk patients. Prophylactic LCSD may provide another option to counter a suboptimal quality of life resulting from medication-related side effects.